Table 2.
Reporting of local adverse reactions in the 7 days after the first and second vaccine dose administration, stratified by symptom severity.
| Dose 1 | Dose 2 | |
|---|---|---|
| N = 296 | N = 275 | |
| Redness, n (% and 95%CI) | ||
| Any | 46 (15.5%, 95%CI 11.6–20.2) | 47 (17.1%, 95%CI 12.8–22.1) |
| Mild | 43 (14.5%, 95%CI 10.7–19.1) | 39 (14.2%, 95%CI 10.3–18.9) |
| Moderate | 3 (1.0%, 95%CI 0.2–2.9) | 6 (2.2%, 95%CI 0.8–4.7) |
| Severe | 0 (0) | 2 (0.7%, 95%CI 0.1–2.6) |
| Grade 4 | 0 (0) | 0 (0) |
| Swelling, n (% and 95%CI) | ||
| Any | 88 (29.7%, 95%CI 24.6–35.3) | 98 (35.6%, 95%CI 30.0–41.6) |
| Mild | 80 (27.0%, 95%CI 22.1–32.5) | 90 (32.7%, 95%CI 27.2–38.6) |
| Moderate | 8 (2.7%, 95%CI 1.2–5.3) | 8 (2.9%, 95%CI 1.3–5.7) |
| Severe | 0 (0) | 0 (0) |
| Grade 4 | 0 (0) | 0 (0) |
| Pain at the injection site, n (% and 95%CI) | ||
| Any | 285 (96.3%, 95%CI 93.4–98.1) | 257 (93.5%, 95%CI 89.9–96.1) |
| Mild | 133 (44.9%, 95%CI 39.2–50.8) | 136 (49.5%, 95%CI 43.4–55.5) |
| Moderate | 146 (49.3%, 95%CI 43.5–55.2) | 116 (42.2%, 95%CI 36.3–48.3) |
| Severe | 6 (2.0%, 95%CI 0.8–4.4) | 5 (1.8%, 95%CI 0.6–4.2) |
| Grade 4 | 0 (0) | 0 (0) |